Ingalls & Snyder LLC Has $14.78 Million Stake in Johnson & Johnson (NYSE:JNJ)

Ingalls & Snyder LLC trimmed its stake in Johnson & Johnson (NYSE:JNJ) by 1.0% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 91,210 shares of the company’s stock after selling 952 shares during the period. Ingalls & Snyder LLC’s holdings in Johnson & Johnson were worth $14,781,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Innealta Capital LLC bought a new stake in Johnson & Johnson in the second quarter valued at $27,000. Highline Wealth Partners LLC bought a new stake in Johnson & Johnson in the third quarter valued at $31,000. RPg Family Wealth Advisory LLC bought a new stake in Johnson & Johnson in the third quarter valued at $35,000. Mowery & Schoenfeld Wealth Management LLC grew its position in Johnson & Johnson by 58.7% in the third quarter. Mowery & Schoenfeld Wealth Management LLC now owns 246 shares of the company’s stock valued at $40,000 after acquiring an additional 91 shares during the period. Finally, Activest Wealth Management bought a new stake in shares of Johnson & Johnson during the third quarter worth $40,000. 69.55% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

JNJ has been the topic of several research analyst reports. Guggenheim increased their target price on Johnson & Johnson from $156.00 to $162.00 and gave the stock a “neutral” rating in a report on Wednesday, November 6th. Royal Bank of Canada upped their price target on Johnson & Johnson from $178.00 to $181.00 and gave the company an “outperform” rating in a research note on Wednesday, October 16th. Wolfe Research assumed coverage on Johnson & Johnson in a research note on Friday, November 15th. They set an “outperform” rating and a $190.00 price target on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $215.00 price target on shares of Johnson & Johnson in a research note on Wednesday, October 16th. Finally, Morgan Stanley increased their target price on Johnson & Johnson from $169.00 to $175.00 and gave the company an “equal weight” rating in a research note on Wednesday, October 16th. Seven investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $175.67.

Johnson & Johnson Stock Down 0.8 %

JNJ stock traded down $1.30 during mid-day trading on Tuesday, reaching $153.50. The company had a trading volume of 1,105,238 shares, compared to its average volume of 7,024,212. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79. The stock has a 50 day simple moving average of $159.15 and a two-hundred day simple moving average of $156.46. The company has a market capitalization of $369.57 billion, a price-to-earnings ratio of 22.40, a PEG ratio of 2.75 and a beta of 0.51. Johnson & Johnson has a 52 week low of $143.13 and a 52 week high of $168.85.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, October 15th. The company reported $2.42 EPS for the quarter, topping the consensus estimate of $2.21 by $0.21. The company had revenue of $22.47 billion during the quarter, compared to the consensus estimate of $22.17 billion. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. The firm’s revenue for the quarter was up 5.2% compared to the same quarter last year. During the same period in the previous year, the company posted $2.66 EPS. As a group, equities analysts predict that Johnson & Johnson will post 9.93 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Tuesday, November 26th will be issued a dividend of $1.24 per share. The ex-dividend date is Tuesday, November 26th. This represents a $4.96 annualized dividend and a yield of 3.23%. Johnson & Johnson’s payout ratio is currently 71.78%.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.